University of Lynchburg DMSc Doctoral Project Assignment Repository
Specialty
Family Medicine
Abstract
Advances in migraine pathophysiology have identified calcitonin gene-related peptide (CGRP) as a key mediator of migraine, leading to the development of targeted preventive therapies. Atogepant is an oral, once-daily CGRP receptor antagonist for the prevention of episodic and chronic migraine. This review synthesizes the efficacy, safety, and tolerability of atogepant in reducing mean monthly migraine days (MMDs) and monthly headache days (MHDs) in patients with episodic and chronic migraine. A comprehensive PubMed search identified multiple randomized clinical trials (RCTs), systematic reviews, meta-analyses, and real-world studies demonstrating a significant reduction in MMDs and MHDs compared with placebo. Additional benefits include decreased use of acute migraine medications and increased responder rates. Atogepant was well tolerated, with primarily mild-to-moderate gastrointestinal adverse events, and had a low treatment discontinuation rate. Further research is imperative to clarify long-term safety, durability of response, and comparative effectiveness within the established migraine treatment paradigms.
Recommended Citation
Bobis S. Atogepant: Review in the Preventive Treatment for Episodic and Chronic Migraine. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2026; 8(1).
Restricted
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.